
1. Nature. 2021 Oct 21. doi: 10.1038/s41586-021-04120-y. [Epub ahead of print]

Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2
vaccination.

Pozzetto B(#)(1)(2), Legros V(#)(1)(3), Djebali S(#)(1), Barateau V(#)(1),
Guibert N(4), Villard M(1), Peyrot L(1), Allatif O(1), Fassier JB(4),
Massardier-Pilonchéry A(4), Brengel-Pesce K(5), Yaugel-Novoa M(1), Denolly S(1), 
Boson B(1), Bourlet T(1), Bal A(1)(6), Valette M(6), Andrieu T(7), Lina B(1)(6); 
Covid-Ser study group, Cosset FL(8), Paul S(9), Defrance T(10), Marvel J(11),
Walzer T(12), Trouillet-Assant S(13)(14).

Collaborators: Saker K, Compagnon C, Mokdad B, d'Aubarede C, Pitiot V, Escuret V,
Morfin F, Trabaud MA, Prieux M, Dubois V, Josset L, Daniel S.

Author information: 
(1)CIRI (Centre International de Recherche en Infectiologie), Université de Lyon,
Université Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon,
Université Jean Monnet de Saint-Etienne, Lyon, France.
(2)Immunology laboratory, CIC1408, CHU Saint-Etienne, Saint-Etienne, France.
(3)Campus Vétérinaire de Lyon, VetAgro Sup, Université de Lyon, Marcy-l'Etoile,
France.
(4)Occupational Health and Medicine Department, Hospices Civils de Lyon,
Université Claude Bernard Lyon1, Ifsttar, UMRESTTE, UMR T_9405, Université de
Lyon, Lyon, France.
(5)Joint Research Unit Civils Hospices of Lyon-bioMérieux, Hospices Civils de
Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
(6)Virology Laboratory, Institute of Infectious Agents, Laboratory Associated
with the National Reference Centre for Respiratory Viruses, Hospices Civils de
Lyon, Lyon, France.
(7)Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR5286,
Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon,
France.
(8)CIRI (Centre International de Recherche en Infectiologie), Université de Lyon,
Université Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon,
Université Jean Monnet de Saint-Etienne, Lyon, France. flcosset@ens-lyon.fr.
(9)CIRI (Centre International de Recherche en Infectiologie), Université de Lyon,
Université Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon,
Université Jean Monnet de Saint-Etienne, Lyon, France.
stephane.paul@chu-st-etienne.fr.
(10)CIRI (Centre International de Recherche en Infectiologie), Université de
Lyon, Université Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon,
Université Jean Monnet de Saint-Etienne, Lyon, France.
thierry.defrance@inserm.fr.
(11)CIRI (Centre International de Recherche en Infectiologie), Université de
Lyon, Université Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon,
Université Jean Monnet de Saint-Etienne, Lyon, France.
jacqueline.marvel@inserm.fr.
(12)CIRI (Centre International de Recherche en Infectiologie), Université de
Lyon, Université Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon,
Université Jean Monnet de Saint-Etienne, Lyon, France. thierry.walzer@inserm.fr.
(13)CIRI (Centre International de Recherche en Infectiologie), Université de
Lyon, Université Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon,
Université Jean Monnet de Saint-Etienne, Lyon, France. sophie.assant@chu-lyon.fr.
(14)Joint Research Unit Civils Hospices of Lyon-bioMérieux, Hospices Civils de
Lyon, Lyon Sud Hospital, Pierre-Bénite, France. sophie.assant@chu-lyon.fr.
(#)Contributed equally

Following severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19
vaccine1,2, European health authorities recommended that patients under the age
of 55 years who received one dose of ChAdOx1-S-nCoV-19 receive a second dose of
the Pfizer BNT162b2 vaccine as a booster. However, the effectiveness and the
immunogenicity of this vaccination regimen have not been formally tested. Here we
show that the heterologous ChAdOx1-S-nCoV-19 and BNT162b2 combination confers
better protection against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection than the homologous BNT162b2 and BNT162b2 combination in a
real-world observational study of healthcare workers (n = 13,121). To understand 
the underlying mechanism, we conducted a longitudinal survey of the anti-spike
immunity conferred by each vaccine combination. Both combinations induced strong 
anti-spike antibody responses, but sera from heterologous vaccinated individuals 
displayed a stronger neutralizing activity regardless of the SARS-CoV-2 variant. 
This enhanced neutralizing potential correlated with increased frequencies of
switched and activated memory B cells that recognize the SARS-CoV-2 receptor
binding domain. The ChAdOx1-S-nCoV-19 vaccine induced a weaker IgG response but a
stronger T cell response than the BNT162b2 vaccine after the priming dose, which 
could explain the complementarity of both vaccines when used in combination. The 
heterologous vaccination regimen could therefore be particularly suitable for
immunocompromised individuals.

© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

DOI: 10.1038/s41586-021-04120-y 
PMID: 34673755 

